Introduction {#Sec1}
============

Prostate cancer is the most commonly diagnosed non-skin cancer and the third leading cause of cancer death among men in the United States \[[@CR1]\], with higher mortality rates among African-Americans compared to Caucasians \[[@CR2]\]. Clinical diagnostic characteristics also affect prostate cancer mortality and biochemical recurrence rates. Those men present with a biopsy Gleason score of eight or greater, clinical tumor stage of T2c or greater, or serum prostate specific antigen (PSA) level of greater than 20 ng/ml are at high risk of disease recurrence \[[@CR3]\] and mortality \[[@CR4]\] even after radical prostatectomy, while men with a Gleason score of less than seven, tumor stage of T2a or less, or PSA of less than 10 ng/ml are unlikely to die from prostate cancer \[[@CR5]\]. Furthermore, compared to Caucasians with similar clinical presentation, African-American men continue to show higher rates of biochemical recurrence after prostatectomy \[[@CR6]\], suggesting other genetic and/or environmental factors contribute to prostate cancer recurrence and mortality.

Glutathione *S*-transferases (GSTs) are an important family of enzymes involved in the biosynthesis and metabolism of many substances \[[@CR7]\] including the detoxification of exogenous carcinogenic chemicals such as polycyclic aromatic hydrocarbons (PAH), which are found in many common exposures such as cigarette smoke, diesel fuel and grilled meats. GSTs may also detoxify reactive endogenous steroid hormone metabolites such as estradiol (E2)-quinones and reactive oxygen species (ROS), which may arise from multiple sources including inflammation and the futile redox cycling of E2- and PAH-quinones \[[@CR8], [@CR9]\]. Specific GST isoforms in the μ (M1), θ (T1) and π (P1) classes are highly expressed in the prostate \[[@CR10], [@CR11]\]; therefore, genetic polymorphisms that modify activity of these GSTs can affect the level of carcinogenic metabolites in the prostate, which, in turn, may alter the risk of prostate cancer recurrence and mortality as well as its incidence.

Functional genetic variants in GSTs, predominantly the GSTM1 null, GSTT1 null and GSTP1 Ile105Val polymorphisms, have been associated inconsistently with prostate cancer incidence; and authors of a recent meta-analysis concluded that the GSTM1 null, GSTT1 null and GSTP1 Ile105Val polymorphisms were unlikely to be major determinants of prostate cancer susceptibility on a wide population basis \[[@CR12]\]. However, this meta-analysis was conducted using Caucasian and Asian populations only and did not include any studies with subjects of African descent. This is a critical point because we have previously shown that allele frequencies and associations between GST polymorphisms and PAH-DNA adduct levels are significantly different among African-American compared to Caucasian men \[[@CR13]\]. Furthermore, the GSTM1-null genotype has been shown to increase risk of prostate cancer mortality in Caucasian men \[[@CR14]\]; however, no prior studies have examined potential effects of these GST polymorphisms on prostate cancer biochemical recurrence risk in African-American men.

Therefore, we examined the potential associations between the GSTM1-null, GSTT1-null and GSTP1 Ile105Val polymorphisms and prostate cancer biochemical recurrence within 5 years after prostatectomy surgery in 168 African-American and 226 Caucasian patients treated at the Henry Ford Hospital in Detroit, Michigan. We also evaluated potential differential associations between these GST polymorphisms and prostate cancer BCR by ethnicity and clinical measures of disease severity at diagnosis.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

The study population from which the subjects used in this analysis were derived has been previously described \[[@CR15]\]. Briefly, 637 cases with a histologically confirmed prostate cancer diagnosis within the last 2 years that were treated at the Henry Ford Hospital in Detroit, Michigan were enrolled within 2 years after diagnosis between 1 July 2001 and 31 December 2004 for an observational prostate cancer case--control study. Of the 637 cases, 429 (67%) underwent radical prostatectomy and were followed from the date of surgery forward using electronic medical records to retrieve all prostate specific antigen (PSA) test results. We excluded the 20 cases that had no follow-up or only one PSA test after surgery and 14 men who also underwent hormone treatment. One case was excluded because of missing tumor grade information. The remaining 394 men comprised the analytic study sample, which had data on 4,459 follow-up PSA test results, ranging from 2 to 54 tests and a median of ten PSA tests per subject. All protocols used in this study were reviewed and approved by the Henry Ford Hospital Institutional Review Board and all study participants provided informed consent.

Genotyping {#Sec4}
----------

Standard venipuncture was used to collect blood samples from all study participants in tubes with EDTA as an anticoagulant. Genomic DNA was extracted from buffy coats using QIAmp DNA Blood kit (Qiagen Inc., Valencia, CA). All purified DNA samples were diluted to a constant DNA concentration in 10 mmol/L Tris, 1 mmol/L EDTA buffer (pH 8).

The GSTP1 Ile105Val (rs947894) polymorphism was detected using the Invader assay with reagents developed by Third Wave Technologies, Inc. (Madison, WI), which uses primers 5′-ACC CCA GGG CTC TAT GGG AA-3′ and 5′-TGA GGG CAC AAG AAG CCC CT-3′ followed by digestion with Alw261. Separation of PCR products, either a 176 bp (GSTP1 Ile) or 91 and 85 bp (GSTP Val), was done on a 3.5% agarose gel.

The full deletion of GSTM1 and GSTT1 was detected by PCR with β-globin as an internal control by the method of Arand et al. with modifications \[[@CR16], [@CR17]\]. Primers used were 5′-GAACTCCCTGAAAAGCTAAAGC-3′ and 5′-GTTGGGCTCAAATATACGGTGG-3′ for GSTM1 or 5′-TTCCTTACTGGTCCTCACATCT-3′ and 5′-TCACCGGATCATGGCCAGCA-3′ for GSTT1 and 5′-GAAGAGCCAAGGACAGGTAC-3′ and 5′-CAACTTCATCCACGTTCACC-3′ for β-globin. DNA (50 ng) was amplified in a reaction volume of 25 μl with 10 pmol of each of the primers, 1.5 mM MgCl2 and 1.5 U AmpliTaq Gold DNA polymerase. Cycling conditions were 10 min at 94°C, followed by 35 cycles (GSTM1) or 30 cycles (GSTT1) of 94°C for 1 min, 62°C for 1 min, 72°C for 1 min and a final extension at 72°C for 5 min. PCR products were separated on a 2% agarose gel and GSTM1 identified by a 215 bp band, GSTT1 by a 473 bp band and β-globin by a 268 bp band.

Statistical analysis {#Sec5}
--------------------

Hazard ratios (HRs) for prostate cancer biochemical recurrence (BCR) by genotype status for the GSTM1-null, GSTT1-null and GSTP1 Ile105Val polymorphisms were estimated with a Cox proportional hazard model using PROC PHREG in SAS v9.1 (SAS Institute, Inc., Cary, NC). Following Freedland et al. \[[@CR18]\] and Kupelian et al. \[[@CR19]\], we defined a BCR event as having two consecutive detectable (PSA \> 0.2 ng/mL) increasing PSA levels for four or more weeks after surgery. Time to event was defined as the duration between the date of surgery and the second PSA test that defined the recurrence event. Patients did not recur were censored at the last post-operative PSA test. Differences in survival curves were tested using the Wilcoxon rank test using PROC LIFETEST in SAS v9.1 (SAS Institute, Inc., Cary, NC). All models were adjusted for age, race, smoking, tumor stage, tumor (Gleason score) grade and PSA level at diagnosis. We evaluated potential confounding by race (population stratification) in a subset of African-American cases (*n* = 146) with African ancestry scores, which we estimated using ADMIXMAP software (<http://homepages.ed.ac.uk/pmckeigu/admixmap>) \[[@CR20]\] and a standard panel of ancestry informative markers (<http://www.illumina.com/pages.ilmn?ID=235>). We also examined potential confounding by PAH-DNA adduct levels in a subset of patients (*N* = 368) with PAH-DNA adduct data available. We investigated whether GST polymorphisms were associated with BCR of prostate cancer in subgroups defined by race (Caucasian, African-American) and clinical risk factors (clinical tumor stage, tumor grade (from biopsy Gleason score) and PSA level at diagnosis). All reported *p*-values are from two-sided tests.

Results {#Sec6}
=======

Characteristics of the study population are shown in Table [1](#Tab1){ref-type="table"}. Biochemical recurrence (BCR) of prostate cancer was experienced by 76 men (19.3%). Men with a BCR event had an average follow-up time of 66.9 months, which was not significantly different from the mean follow-up time of men not having a BCR event (61.0 months); however, for purposes of the analyses and presentation of survival data, follow-up time was censored at 60 months (5 years). Those men that experienced BCR were more likely to have tumors with an advanced stage (T3 or higher), high tumor grade (total Gleason score ≥8 or primary Gleason ≥4), and higher PSA level at diagnosis. The mean age at diagnosis, smoking status and race were not significantly different between men with a BCR event and those not experiencing BCR. Genotype frequencies for the GSTM1 null, GSTT1 null and GSTP1 Ile105Val polymorphisms were not significantly different between men with and without recurrence. In addition, the number of GST variant (risk) alleles was also not significantly different between the two groups.Table 1Characteristics of 394 prostate cancer cases by biochemical recurrence (BCR) status following prostatectomy surgeryCharacteristicBCR (*n* = 76)No BCR (*n* = 318)*p*-value^a^Age (mean ± SE)60.8 ± 6.061.0 ± 6.80.73African-Americans (%)30 (39.5%)138 (43.4%)0.53Average time of follow-up/observation (months)^b^66.9 ± 24.761.0 ± 22.70.09PSA at diagnosis (ng/ml)10.6 ± 9.66.0 ± 4.3\<0.001High tumor grade^c^35 (46.1%)77 (24.2%)\<0.001Advanced tumor stage^d^30 (39.7%)43 (13.5%)\<0.001Cigarette smoking status    Never23 (33.3%)119 (38.1%)0.42    Former46 (60.5%)156 (51.7%)    Current7 (9.2%)33 (10.3%)GSTM1 null32 (42.1%)123 (38.7%)0.58GSTT1 null15 (19.7%)67 (21.1%)0.80GSTP1 Ile105Val    Ile/Ile26 (34.2%)117 (36.8%)0.22    Ile/Val34 (44.7%)159 (50.0%)    Val/Val16 (21.1%)42 (13.2%)Total number of high risk genotypes (combined)^e^    011 (14.5%)53 (16.7%)0.96    136 (47.4%)149 (46.9%)    226 (32.4%)106 (33.3%)    33 (4.0%)10 (3.1%)^a^*p*-value from *t*-test or χ^2^ test, as applicable^b^Time from study entry to date of last PSA test for the entire cohort^c^High-grade defined as a total Gleason score of eight or higher or a primary Gleason score of four or higher^d^Advanced tumor stage defined as Stage 3a or higher^e^Number of GSTM1 null, GSTT1 null and GSTP1 105Val alleles

Kaplan-Meier curves for prostate cancer BCR in the GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms were not significantly different (Fig. [1](#Fig1){ref-type="fig"}a--d). For the GSTM1 null (Fig. [1](#Fig1){ref-type="fig"}, Panel a) and GSTP1 105 Val/Val (Fig. [1](#Fig1){ref-type="fig"}, Panel c) genotypes, BCR was higher at 2 to 3 years of follow-up, but the survival curves tended to move toward each other at 5 years. In models adjusted for age, race, smoking, tumor stage, tumor grade and PSA at baseline (Table [2](#Tab2){ref-type="table"}), a non-statistically significant increased risk of BCR was observed in men with the GSTM1 null (HR = 1.41; 95% CI 0.88--2.26; *p* = 0.16) and GSTT1 null (HR = 1.11; 95% CI 0.63--1.96; *p* = 0.72) genotypes compared to those with GSTM1 and GSTT1 present, respectively. Similarly, we observed no statistically significant association between the GSTP1 Ile105Val polymorphism and prostate cancer BCR, with the largest effect size observed with a recessive genetic model (i.e., GSTP1 105 Val/Val versus Ile/Ile or Ile/Val: HR = 1.62; 95% CI 0.87--2.68; *p* = 0.14). We also examined the total number of putative high risk (variant) GST genotypes and under an additive model (i.e., having 1, 2, or all 3 GST variants (GSTM1 null, GSTT1 null and/or GSTP1 105 Ile/Val or Val/Val) versus having no GST variants (GSTM1 present, GSTT1 present and GSTP1 105 Ile/Ile) we observed no significant increased BCR risk (HR = 1.15; 95% CI 0.85--1.56; *p* = 0.37).Fig. 1Kaplan--Meier survival curves for biochemical recurrence of prostate cancer for GST polymorphisms: **a** GSTM1 null versus GSTM1 present (log rank *p* = 0.4); **b** GSTT1 null versus GSTT1 present (log rank *p* = 0.9); **c** GSTP1 codon 105 Ile/Ile versus Ile/Val versus Val/Val (log rank *p* = 0.2) and **d** total number of GST high risk (variant) genotypes (log rank *p* = 0.9)Table 2Risk of prostate cancer biochemical recurrence after prostatectomy associated with GST polymorphisms by racePolymorphismTotal sample (*n* = 394)Caucasians (*n* = 226)African-Americans (*n* = 168)*P*-value^a^GSTM1 null1.41 (0.88--2.26); *p* = 0.16\
(*N*~H1~ = 32; *N*~R~ = 44)^b^1.61 (0.89--2.96); *p* = 0.11\
(*N*~H1~ = 24; *N*~R~ = 22)1.11 (0.44--2.40); *p* = 0.95\
(*N*~H1~ = 8; N~R~ = 22)0.62GSTT1 null1.11 (0.63--1.96); *p* = 0.72\
(*N*~H1~ = 15; *N*~R~ = 61)0.55 (0.21--1.40); *p* = 0.20\
(*N*~H1~ = 5; *N*~R~ = 41)2.30 (1.01--5.18); *p* = 0.04\
(*N*~H1~ = 10; *N*~R~ = 20)0.02GSTP1 Ile105Val*Co-dominant*Ile/Val vs. Ile/Ile0.81 (0.48--1.39); *p* = 0.44\
(*N*~H1~ = 16; *N*~R~ = 34)0.54 (0.27--1.08); *p* = 0.08\
(*N*~H1~ = 9; *N*~R~ = 17)1.71 (0.64--4.55); *p* = 0.28\
(*N*~H1~ = 7; *N*~R~ = 17)0.22Val/Val vs. Ile/Ile1.35 (0.71--2.57); *p* = 0.37\
(*N*~H1~ = 16; *N*~R~ = 26)0.96 (0.40--2.28); *p* = 0.93\
(*N*~H1~ = 9; *N*~R~ = 20)2.10 (0.66--6.67); *p* = 0.21\
(*N*~H1~ = 7; *N*~R~ = 6)0.50*Recessive*Val/Val vs. Ile/Val or Ile/Ile1.62 (0.87--2.68); *p* = 0.14\
(*N*~H1~ = 16; *N*~R~ = 60)1.39 (0.64--3.00); *p* = 0.42\
(*N*~H1~ = 9; N~R~ = 37)1.45 (0.59--3.55); *p* = 0.42\
(*N*~H1~ = 7; *N*~R~ = 23)0.96*Dominant*Ile/Val or Val/Val vs. Ile/Ile0.93 (0.57--1.53); *p* = 0.78\
(*N*~H1~ = 50; *N*~R~ = 26)0.62 (0.33--1.18); *p* = 0.15\
(*N*~H1~ = 26; *N*~R~ = 20)1.81 (0.71--4.63); *p* = 0.22\
(*N*~H1~ = 24; *N*~R~ = 6)0.26*Additive*Ile/Val vs. Val/Val vs. Ile/Ile1.11 (0.79--1.57); *p* = 0.54\
(*N*~H1~ = 16; *N*~H2~ = 34; *N*~R~ = 26)0.87 (0.55--1.39); *p* = 0.56\
(*N*~H1~ = 9; *N*~H2~ = 17; *N*~R~ = 20)1.44 (0.83--2.52); *p* = 0.20\
(*N*~H1~ = 7; *N*~H2~ = 17; *N*~R~ = 6)0.35Total number of high risk GST genotypes^c^1.15 (0.85--1.56); *p* = 0.37\
(*N*~H1~ = 3; *N*~H2~ = 26; *N*~H3~ = 36; *N*~R~ = 11)0.92 (0.64--1.32); *p* = 0.65\
(*N*~H1~ = 0; *N*~H2~ = 17; *N*~H3~ = 21; *N*~R~ = 8)1.89 (1.06--3.40); *p* = 0.03\
(*N*~H1~ = 3; *N*~H2~ = 9; *N*~H3~ = 15; *N*~R~ = 3)0.04Hazard ratio (HR) and the 95% confidence interval (CI) adjusted for age, race, smoking, tumor stage, tumor grade and PSA at diagnosis^a^*p*-value for race × genotype interaction^b^Number of events in putative high risk groups (*N*~h1~, *N*~h2~, *N*~h3~) versus low risk referent group (*N*~R~)^c^Additive risk of having 1, 2 or 3 of the GSTM1 null, GSTT1 null and GSTP1 105 Ile/Val or Val/Val genotypes versus having no variant genotypes

When we stratified by race (Table [2](#Tab2){ref-type="table"}), however, we found that the GSTT1 null genotype increased risk in African-Americans (HR = 2.30; 95% CI = 1.01--5.18; *p* = 0.04) but not in Caucasians (*p*-value for the race × genotype interaction term (*p*~int~) = 0.02). The GSTM1 null genotype conferred a modest, non-statistically significant increased risk of BCR in Caucasians (HR = 1.61; 95% CI = 0.89--2.96; *p* = 0.11), but the effect size in African-Americans was not much different than 1.0 (HR = 1.11; 95% CI = 0.44--2.40; *p* = 0.95). No significant association was observed for either Caucasian or African-American men with the GSTP1 105Val variant allele under any genetic model (recessive, dominant, or additive). Interestingly, in African-Americans, the total number of high risk GST genotypes under an additive genetic model was associated with an increased BCR risk (HR = 1.89; 95% CI 1.06--3.40; *p* = 0.03), but this association was not observed in Caucasians (*p*~int~ = 0.04).

We next examined potential associations between GST polymorphisms and prostate cancer BCR by measures of disease severity at diagnosis. Kaplan--Meier curves for BCR for each of the three GST polymorphisms and the combined high risk genotypes by tumor grade are shown in Fig. [2](#Fig2){ref-type="fig"}a--d. When stratifying by genotype, patients with high grade tumors had increased prostate cancer BCR if they had the GSTT1 null (Fig. [2](#Fig2){ref-type="fig"}, Panel b: Log Rank *p* = 0.003) or the GSTP1 105 Ile/Val or Val/Val (Panel c: Log Rank *p* = 0.003) genotypes. However, further stratification by race revealed that the risk associated with the GSTT1 null and GSTP1 105 Ile/Val or Val/Val genotypes was even greater in African-Americans and essentially absent in Caucasians (Table [3](#Tab3){ref-type="table"}). More specifically, African-Americans with high grade tumors and the GSTT1 null genotype had nearly an eightfold increased risk of BCR compared to African-Americans with low grade tumors and GSTT1 present (HR = 7.82; 95% CI = 2.49--24.50; *p* \< 0.001). In addition, African-American patients with high grade tumors and the GSTP1 105 Ile/Val or Val/Val genotypes had over a threefold increased risk of BCR compared to African-Americans with low grade tumors and the GSTP1 Ile/Ile genotype (HR = 3.68; 95% CI = 1.13--12.04; *p* = 0.03). Caucasian men with high grade tumors and the GSTM1 null genotype had nearly a threefold increased risk of BCR compared to Caucasians with low grade tumors and GSTM1 present (HR = 2.88; 95% CI = 1.16--7.14; *p* = 0.02). Moreover, having two or three compared to one or no high risk (variant) GST genotypes only conferred increased BCR risk in African-Americans with high grade tumors (HR = 4.78; 95% CI = 1.58--14.43; *p* = 0.006).Fig. 2Kaplan--Meier survival curves for biochemical recurrence of prostate cancer for GST polymorphisms in high versus low tumor grade: **a** GSTM1 null versus GSTM1 present (log rank *p* = 0.0002); **b** GSTT1 null versus GSTT1 present (log rank *p* = 0.0001); **c** GSTP1 codon 105 Ile/Ile and Ile/Val versus Val/Val (log rank *p* \< 0.00001) and **d** total number of GST high risk (variant) genotypes (log rank *p* = 0.0001)Table 3Risk of prostate cancer BCR after prostatectomy associated with GST polymorphisms by race and tumor gradeGenotypeTotal sampleCaucasiansAfrican-AmericansLow gradeHigh gradeLow gradeHigh gradeLow gradeHigh gradeGSTM11.00 (referent)\
(*N* = 20)^b^2.45 (1.32--4.53)\
*p* = 0.004 (*N* = 21)1.00 (referent)\
(*N* = 11)2.08 (0.87--4.96)\
*p* = 0.10 (*N* = 15)1.00 (referent)\
(*N* = 9)4.00 (1.60--9.99)\
*p* = 0.003 (*N* = 6)GSTM1 null1.83 (0.97--3.44)\
*p* = 0.06 (*N* = 24)2.48 (1.16--5.30)\
*p* = 0.02 (*N* = 11)1.84 (0.81--4.18)\
*p* = 0.14 (*N* = 11)2.88 (1.16--7.14)\
*p* = 0.02 (*N* = 9)2.04 (0.71--5.83)\
*p* = 0.19 (*N* = 13)1.49 (0.31--7.24)\
*p* = 0.62 (*N* = 2)GSTT11.00 (referent)\
(*N* = 34)1.58 (0.93--2.70)\
*p* = 0.09 (*N* = 7)1.00 (referent)\
(*N* = 24)1.49 (0.78--2.87)\
*p* = 0.23 (*N* = 2)1.00 (referent)\
(*N* = 10)2.21 (0.86--5.64)\
*p* = 0.10 (*N* = 5)GSTT1 null0.72 (0.32--1.64)\
*p* = 0.44 (*N* = 27)3.05 (1.38--6.72)\
*p* = 0.006 (*N* = 8)0.32 (0.08--1.35)\
*p* = 0.12 (*N* = 17)1.59 (0.45--5.67)\
*p* = 0.48 (*N* = 3)1.60 (0.53--4.80)\
*p* = 0.40 (*N* = 10)7.82 (2.49--24.50)\
*p* \< 0.001 (*N* = 5)GSTP1 Ile/Ile1.00 (referent)\
(*N* = 18)1.12 (0.48--2.63)\
*p* = 0.79 (*N* = 23)1.00 (referent)\
(*N* = 14)1.30 (0.50--3.43)\
*p* = 0.59 (*N* = 12)1.00 (referent)\
(*N* = 4)0.80 (0.14--4.52)\
*p* = 0.80 (*N* = 11)GSTP1 Ile/Val or Val/Val0.68 (0.36--1.27)\
*p* = 0.22 (*N* = 8)1.68 (0.87--3.24)\
*p* = 0.12 (*N* = 27)0.50 (0.22--1.13)\
*p* = 0.09 (*N* = 6)1.13 (0.50--2.57)\
*p* = 0.77 (*N* = 14)0.84 (0.26--2.67)\
*p* = 0.76 (*N* = 2)3.68 (1.13--12.04)\
*p* = 0.03 (*N* = 13)0--1 High risk GST alleles^a^1.00 (referent)\
(*N* = 27)1.61 (0.88--2.96)\
*p* = 0.12 (*N* = 14)1.00 (referent)\
(*N* = 18)1.53 (0.70--3.35)\
*p* = 0.28 (*N* = 8)1.00 (referent)\
(*N* = 9)2.34 (0.88--6.22)\
*p* = 0.09 (*N* = 6)2--3 High risk GST alleles0.95 (0.49--1.82)\
*p* = 0.87 (*N* = 20)2.25 (1.22--4.53)\
*p* = 0.01 (*N* = 15)0.74 (0.31--1.74)\
*p* = 0.49 (*N* = 11)1.67 (0.73--3.85)\
*p* = 0.23 (*N* = 9)1.43 (0.50--4.05)\
*p* = 0.51 (*N* = 9)4.78 (1.58--14.43)\
*p* = 0.006 (*N* = 6)Hazard ratio (HR) and the 95% confidence interval (CI) adjusted for age, race, smoking, tumor stage and PSA at diagnosis^a^The number of high risk alleles refers to the total number of GST (GSTM1 null, GSTT1 null and GSTP1 105 Ile/Val or Val/Val) variants and individual carries (0, 1, 2 or 3)^b^Number of biochemical failure events (*N*) in each stratum

We observed similar findings when examining associations for the various GST polymorphisms by clinical tumor stage subgroups. Specifically, we found that patients with high stage tumors had increased prostate cancer BCR if they had the GSTT1 null (Fig. [3](#Fig3){ref-type="fig"}, Panel b: Log Rank *p* \< 0.0001) or the GSTP1 105 Ile/Val or Val/Val (Panel c: Log Rank *p* = \<0.0001) genotypes. Furthermore, as shown in Table [4](#Tab4){ref-type="table"}, men with high stage tumors and the GSTM1 null genotype had an increased BCR risk compared to those with low stage tumors and GSTM1 present (HR = 3.58; 95% CI = 1.82--7.05; *p* \< 0.001); however, stratifying by race revealed that this association only remained significant among Caucasians (HR = 4.89; 95% CI = 2.10--11.43; *p* \< 0.001). African-Americans with high stage tumors, however, had increased BCR when they had the GSTT1 null (HR = 6.20; 95% CI = 1.63--23.58; *p* = 0.008) or the GSTP1 105 Ile/Val or Val/Val (HR = 3.94; 95% CI = 1.25--12.43) genotype compared to African-Americans with low stage tumors and GSTT1 present or GSTP1 105 Ile/Ile, respectively. Similar to the results with high tumor grade, only African-American patients with high stage tumors and two or three compared to one or no high risk (variant) GST genotypes had increased risk of BCR (HR = 3.60; 95% CI = 1.11--11.65; *p* = 0.03).Fig. 3Kaplan--Meier survival curves for biochemical recurrence of prostate cancer for GST polymorphisms in high versus low tumor stage: **a** GSTM1 null versus GSTM1 present (log rank *p* \< 0.0001); **b** GSTT1 null versus GSTT1 present (log rank *p* \< 0.0001); **c** GSTP1 codon 105 Ile/Ile and Ile/Val versus Val/Val (log rank *p* \< 0.0001) and **d** total number of GST high risk (variant) genotypes (log rank *p* \< 0.0001)Table 4Risk of prostate cancer BCR after prostatectomy associated with GST polymorphisms by race and tumor stageGenotypeTotal sampleCaucasiansAfrican-AmericansLow stageHigh stageLow stageHigh stageLow stageHigh stageGSTM11.00 (referent)\
(*N* = 27)^b^2.48 (1.31--4.69)\
*p* = 0.005 (*N* = 19)1.00 (referent)\
(*N* = 13)2.98 (1.23--7.21)\
*p* = 0.02 (*N* = 14)1.00 (referent)\
(*N* = 14)2.97 (1.16--7.62)\
*p* = 0.02 (*N* = 5)GSTM1 null1.38 (0.75--2.53)\
*p* = 0.30 (*N* = 17)3.58 (1.82--7.05)\
*p* \< 0.001 (*N* = 13)1.61 (0.73--3.53)\
*p* = 0.24 (*N* = 9)4.89 (2.10--11.43)\
*p* \< 0.001 (*N* = 10)1.36 (0.48--3.86)\
*p* = 0.57 (*N* = 8)2.01 (0.55--7.30)\
*p* = 0.29 (*N* = 3)GSTT11.00 (referent)\
(*N* = 35)2.88 (1.68--4.95)\
*p* \< 0.001 (*N* = 11)1.00 (referent)\
(*N* = 23)3.46 (1.82--6.58)\
*p* \< 0.001 (*N* = 4)1.00 (referent)\
(*N* = 12)2.42 (0.91--6.45)\
*p* = 0.08 (*N* = 7)GSTT1 null1.34 (0.68--2.65)\
*p* = 0.40 (*N* = 26)2.14 (0.73--6.21)\
*p* = 0.16 (*N* = 4)0.82 (0.28--2.40)\
*p* = 0.72 (*N* = 18)0.76 (0.10--5.97)\
*p* = 0.80 (*N* = 1)2.21 (0.86--5.68)\
*p* = 0.10 (*N* = 8)6.20 (1.63--23.58)\
*p* = 0.008 (*N* = 3)GSTP1 Ile/Ile1.00 (referent)\
(*N* = 18)2.39 (1.03--5.54)\
*p* = 0.04 (*N* = 28)1.00 (referent)\
(*N* = 13)3.53 (1.39--8.97)\
*p* = 0.008 (*N* = 14)1.00 (referent)\
(*N* = 5)0.81 (0.09--7.08)\
*p* = 0.85 (*N* = 14)GSTP1 Ile/Val or Val/Val0.89 (0.49--1.63)\
*p* = 0.70 (*N* = 8)2.42 (1.23--4.76)\
*p* = 0.01 (*N* = 22)0.66 (0.30--1.46)\
*p* = 0.30 (*N* = 7)2.01 (0.86--4.71)\
*p* = 0.11 (*N* = 12)1.24 (0.43--3.56)\
*p* = 0.69 (*N* = 1)3.94 (1.25--12.43)\
*p* = 0.02 (*N* = 10)0--1 High risk GST alleles^a^1.00 (referent)\
(*N* = 28)2.85 (1.56--5.23)\
*p* \< 0.001 (*N* = 18)1.00 (referent)\
(*N* = 17)3.66 (1.72--7.78)\
*p* \< 0.001 (*N* = 10)1.00 (referent)\
(*N* = 11)2.69 (0.95--7.65)\
*p* = 0.06 (*N* = 8)2--3 High risk GST alleles^a^1.29 (0.71--2.35)\
*p* = 0.40 (*N* = 19)2.78 (1.35--5.75)\
*p* = 0.006 (*N* = 11)1.08 (0.48--2.40)\
*p* = 0.85 (*N* = 12)2.47 (0.98--6.24)\
*p* = 0.06 (*N* = 7)1.91 (0.75--4.84)\
*p* = 0.17 (*N* = 7)3.60 (1.11--11.65)\
*p* = 0.03 (*N* = 4)Hazard ratio (HR) and the 95% confidence interval (CI) adjusted for age, race, smoking, tumor grade and PSA at diagnosis^a^The number of high risk alleles refers to the number of GST (GSTM1 null, GSTT1 null and GSTP1 105 Ile/Val or Val/Val) variants carried^b^Number of biochemical failure events (*N*) in each stratum

Men with more aggressive (high grade or high stage) tumors carrying the GSTM1 null genotype had an increased risk of BCR compared to those with less aggressive (low grade or low stage) disease and GSTM1 present (HR = 3.75; 95% CI = 1.85--7.61; *p* \< 0.001); however, after stratifying by race, this association only remained statistically significant in Caucasians (HR = 4.26; 95% CI = 1.73--10.48; *p* = 0.002) (Table [5](#Tab5){ref-type="table"}). African-Americans with more aggressive disease carrying the GSTT1 null genotype had increased BCR compared to those with less aggressive disease and GSTT1 present (HR = 5.61; 95% CI = 1.72--18.36; *p* = 0.004). Furthermore, men with more aggressive disease carrying 2--3 GST variants compared to those with less aggressive disease carrying none or one GST variant had an increased risk of BCR (HR = 3.00; 95% CI = 1.55--5.78; *p* = 0.001), but this association was stronger in African-Americans (HR = 5.14; 95% CI = 1.65--16.07; *p* = 0.005) than in Caucasians (HR = 2.29; 95% CI = 1.02--5.13; *p* = 0.05).Table 5Risk of prostate cancer BCR after prostatectomy associated with GST polymorphisms by race and tumor aggressiveness statusGenotypeTotal sampleCaucasiansAfrican-AmericansLow aggressiveHigh aggressiveLow aggressiveHigh aggressiveLow aggressiveHigh aggressiveGSTM1 present1.00 (referent)\
(*N* = 15)^b^2.85 (1.52--5.34)\
*p* = 0.001 (*N* = 29)1.00 (referent)\
(*N* = 8)2.73 (1.13--6.56)\
*p* = 0.03 (*N* = 14)1.00 (referent)\
(*N* = 7)3.44 (1.37--8.65)\
*p* = 0.009 (*N* = 15)GSTM1 null1.95 (0.96--4.00)\
*p* = 0.07 (*N* = 16)3.75 (1.85--7.61)\
*p* \< 0.001 (*N* = 16)1.98 (0.76--5.14)\
*p* = 0.16 (*N* = 11)4.26 (1.73--10.48)\
*p* = 0.002 (*N* = 13)2.06 (0.64--6.62)\
*p* = 0.22 (*N* = 5)2.72 (0.70--10.61)\
*p* = 0.15 (*N* = 3)GSTT1 present1.00 (referent)\
(*N* = 24)2.38 (1.42--4.01)\
*p* = 0.001 (*N* = 37)1.00 (referent)\
(*N* = 17)2.34 (1.25--4.38)\
*p* = 0.008 (*N* = 24)1.00 (referent)\
(*N* = 7)2.85 (1.10--7.43)\
*p* = 0.03 (*N* = 13)GSTT1 null1.10 (0.48--2.56)\
*p* = 0.82 (*N* = 7)2.53 (1.13--5.64)\
*p* = 0.02 (*N* = 8)0.52 (0.12--2.26)\
*p* = 0.38 (*N* = 2)1.34 (0.39--4.62)\
*p* = 0.65 (*N* = 3)2.20 (0.69--6.97)\
*p* = 0.18 (*N* = 5)5.61 (1.72--18.36)\
*p* = 0.004 (*N* = 5)GSTP1 Ile/Ile1.00 (referent)\
(*N* = 14)1.44 (0.66--3.15)\
*p* = 0.35 (*N* = 12)1.00 (referent)\
(*N* = 11)1.83 (0.75--4.48)\
*p* = 0.18 (*N* = 9)1.00 (referent)\
(*N* = 3)1.07 (0.21--3.04)\
*p* = 0.94 (*N* = 3)GSTP1 Ile/Val or Val/Val0.62 (0.30--1.27)\
*p* = 0.19 (*N* = 17)1.92 (1.00--3.68)\
*p* = 0.05 (*N* = 33)0.49 (0.19--1.28)\
*p* = 0.14 (*N* = 8)1.56 (0.71--3.44)\
*p* = 0.27 (*N* = 18)0.82 (0.22--3.04)\
*p* = 0.77 (*N* = 9)3.01 (0.85--10.71)\
*p* = 0.09 (*N* = 15)0--1 High risk GST alleles^a^1.00 (referent)\
(*N* = 19)2.29 (1.27--4.12)\
*p* = 0.006 (*N* = 28)1.00 (referent)\
(*N* = 13)2.30 (1.10--4.80)\
*p* = 0.03 (*N* = 16)1.00 (referent)\
(*N* = 6)2.81 (1.02--7.76)\
*p* = 0.05 (*N* = 12)2--3 High risk GST alleles^a^1.20 (0.58--2.49)\
*p* = 0.62 (*N* = 12)3.00 (1.55--5.78)\
*p* = 0.001 (*N* = 17)0.90 (0.34--2.40)\
*p* = 0.83 (*N* = 6)2.29 (1.02--5.13)\
*p* = 0.05 (*N* = 11)1.87 (0.59--5.87)\
*p* = 0.29 (*N* = 6)5.14 (1.65--16.07)\
*p* = 0.005 (*N* = 6)High aggressive = High stage or high grade; Low aggressive = Low stage or low grade; Hazard ratio and 95% confidence interval adjusted for age, race, smoking and PSA at diagnosis^a^The number of high risk alleles refers to the number of GST (GSTM1 null, GSTT1 null and GSTP1 105 Ile/Val or Val/Val) variants carried^b^Number of biochemical failure events (*N*) in each stratum

In a subset of African-American cases for which we also had ancestry informative markers (*N* = 146), we additionally adjusted all models for African ancestry scores (see "[Methods: Statistical Analysis](#Sec5){ref-type="sec"}") and observed no material differences (data not shown). Furthermore, because we previously observed that PAH-DNA adducts in prostate cells were associated with an increased risk of prostate cancer BCR \[[@CR21]\], we also performed all of the aforementioned analyses with additional adjustment for PAH-DNA adduct levels in a subset of patients with PAH-DNA adduct data also available (*N* = 368); and we observed no material differences in any of the results presented (data not shown).

Discussion {#Sec7}
==========

We found that the GSTT1 null and GSTP1 105 Ile/Val and Val/Val variant genotypes increased risk of prostate cancer BCR in African-Americans but not Caucasians with high grade and high stage tumors; and the GSTM1 null variant genotype increased risk of BCR in Caucasians but not African-Americans with high grade and high stage tumors. Effect sizes (HRs) in African-Americans were markedly smaller for the GSTP1 polymorphism (3.68 and 3.94 for high grade and high stage tumors, respectively) compared to those observed for the GSTT1 null polymorphism (7.82 and 6.20 for high grade and high stage tumors, respectively).

In the only prior report examining the potential association between GST polymorphisms and prostate cancer biochemical recurrence, Agalliu et al. \[[@CR14]\] found that in Caucasian men the GSTM1 null genotype increased the risk prostate cancer recurrence by 56%, but this was not statistically significant. Our findings are consistent with these prior results in that we observed a modest (61%) but non-statistically significant increased risk of BCR with the GSTM1 null genotype in our Caucasian patient population. However, we did observe a significant increased risk with the GSTM1 null genotype in Caucasian patients with high grade and advanced (high) stage disease. Agalliu et al. \[[@CR14]\] also reported that neither the GSTT1 null or GSTP1 Ile105Val polymorphisms were associated with recurrence or mortality, which is consistent with our findings among Caucasians but not in African-Americans, where we observed a significant association between the GSTT1 null genotype and BCR, which was markedly increased among African-Americans with high grade and advanced stage disease. Importantly, their study population comprised only a small percentage of patients with high grade tumors (total Gleason score of eight or greater), which may help explain the differences in our results. Furthermore, the Agalliu et al. population was comprised predominantly of Caucasians (95%), which limited their ability to potentially detect the differences we observed when stratifying by race and tumor grade, particularly since African-American men generally present with more advanced disease \[[@CR2]\] and have higher rates of recurrence than Caucasian men \[[@CR6]\]. Moreover, our study population was restricted to those who treated with radical prostatectomy alone, whereas the Agalliu et al. \[[@CR14]\] study population included men who underwent androgen deprivation therapy (ADT) (8.4% with BCR, 2.5% without BCR), ADT and radiation (21.0% with BCR, 16.7% without BCR), and a few men who did not undergo any treatment (3.5% with BCR, 6.2% without BCR) for prostate cancer. Differences in treatment regimes could potentially affect the association between GST polymorphisms and biochemical recurrence due to the numerous functions of GSTs including metabolism of steroid hormones and detoxification of carcinogenic metabolites \[[@CR7]\]. When Agalliu et al. \[[@CR14]\] restricted their analysis to only those treated with radical prostatectomy, they found an even higher risk of recurrence with the GSTM1 null polymorphism, but this result was not statistically significant.

Although a recent meta-analysis suggests polymorphisms in GSTM1 null, GSTT1 null and GSTP1 Ile105Val are unlikely to be major determinants of prostate cancer incidence \[[@CR12]\], our results suggest that GST polymorphisms may play a greater role in recurrence of advanced prostate cancer and effects may differ by race. Specifically, we found that the GSTT1 null and GSTP1 Ile105Val polymorphisms were associated with increased BCR in African-American men but not Caucasian men with high grade and high stage tumors and that the GSTM1 null polymorphism was associated with BCR in Caucasian men but not African-American men with high grade and high stage tumors. Although the total number of high risk (variant) GST genotypes increased BCR risk almost twofold in African-Americans, we did not observe a significant effect with having increasing numbers of GST variants in Caucasians. We hypothesize that the potential role of the GSTP1 polymorphism is complicated by the consistent finding that the GSTP1 promoter region CpG islands are hypermethylated, leading to inactivation of GSTP1 in prostate tumor cells \[[@CR22]\], which may serve as an indicator of biochemical recurrence after radical prostatectomy \[[@CR23]\]. Perhaps, the silencing of GSTP1 in prostate cancer speaks to an even greater role for the GSTM1 null and GSTT1 null polymorphisms in prostate cancer progression, since the partial or complete lack of GSTP1 function would require that GSTM1 or GSTT1 serve as substitutes where there is overlap in their substrate specificities \[[@CR7]\]. Although, why GSTM1 might be more biologically important in Caucasians and GSTT1 in African-Americans is unclear. Differences in patterns of exposure may play a role. For example, we \[[@CR13]\] and others \[[@CR24]\] have observed interactions between the GSTM1 null polymorphism and smoking in Caucasians, but larger studies are needed to better understanding of these and other possible gene--environment interactions.

Strengths of our study include the use of patients who only underwent surgery (radical prostatectomy) for treatment, which prevented confounding by treatment and enabled a uniform definition of disease recurrence. Our study population also had a fairly large representation of African-American patients (42.6%). However, our sample size diminished considerably after further stratifying by genotype and clinical measures. Furthermore, due to the exploratory nature of our analyses, we did not correct for multiple statistical tests. Therefore, our results should be interpreted with caution and require validation in a larger independent study population.

In summary, we found that the GSTT1 null genotype increased risk of BCR in African-American men with prostate cancer, particularly those patients with high grade and high stage tumors. In Caucasians with high grade and high stage tumors, the GSTM1 null genotype increased risk of BCR. Overall, the GST polymorphisms were more strongly associated with BCR risk in African-Americans, suggesting GST-targeted therapeutics may have their greatest impact on treatment of advanced prostate cancers in African-Americans.

This work was supported, in part, by the following grants: NIEHS R01-ES011126, NCI K07-CA129162 and DOD W81XWH-06-1-0181.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
